Methylethylpiridinol (Emoxy-Optic) eye drops 1% – [5 ml vial]

Antioxidant (drug that prevents lipid peroxidation in cell membranes), which has angioprotective (increases vascular resistance), antiaggregative (prevents platelet adhesion) and antihypoxic (increases tissue resistance to oxygen deficiency) activity. It reduces capillary permeability and strengthens the vascular wall (angioprotector). Reduces blood viscosity and platelet aggregation (antiaggregant). Inhibitor of free radical processes, has a membrane stabilizing effect. It has retinoprotective properties, protects the retina and other tissues of the eye from the damaging effects of high intensity light. Promotes resorption of intraocular hemorrhages, reduces blood clotting, improves microcirculation in the eye. Stimulates reparative processes in cornea (including in early postoperative and post-operative period).

In adults with the following diseases and conditions:

– Hemorrhages in the anterior chamber of the eye (treatment);

– Scleral hemorrhages in elderly patients (treatment and prophylaxis);

– Corneal inflammations and burns (treatment and prevention);

– Myopia complications (treatment);

– Corneal protection (when wearing contact lenses).

– pregnancy;

– Lactation (breastfeeding);

– Children and adolescents under 18 years of age;

– Hypersensitivity to the drug components.

Emoxy-Optic  is put into the conjunctival sac in 1-2 drops 2-3 times a day. The course of treatment is 3-30 days. If necessary and well tolerated, treatment can be continued for up to 6 months and may be repeated 2-3 times a year.